DMT Clinical Trial

Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-...

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers.  Both compounds are novel deuterated DMT...

Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Following their arrangement plan under the BC Business Corporations Act, and pursuant to the agreement’s terms, Small Pharma is now a wholly-owned subsidiary...

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants. A DMT formulation, VLS-01 works as a partial agonist of the 5-HT 1A/2A/2C receptors, with an...

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) and psychedelic therapy education organization Fluence have signed an agreement to support the streamlining and scaling of the former’s EMBARK facilitator training program in light of an upcoming global Phase 3 trial of deuterated...

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. They correspond to U.K.’s short-acting psychedelic therapies developer Small Pharma’s (...

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and outstanding securities. The deal has already been unanimously approved by both...

Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for aggregate gross proceeds of $8,250,000. Each unit will equate one common share and one common share...

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and...

Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers....

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials: Cash, cash equivalents and short-term investments of a total $249.9...

Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) announced that the last patient has completed its final visit in its Phase IIa clinical study of its proprietary intravenous (IV) DMT formulation SPL026 paired with supportive therapy for the treatment of Major Depressive...

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands.  CEO Christopher J. Moreau said the company is thrilled to initiate...

Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD). Through its R&D acceleration platform,...

Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has signed an investigator-initiated clinical trial agreement with Yale University -a recurring type of alliance within the psychedelics space- for the study of multiple intravenous (IV) doses of DMT for the...